Full-Time

Territory Management and Sales Incentive Analyst

Posted on 2/21/2026

Sartorius

Sartorius

5,001-10,000 employees

Laboratory instruments and bioprocess solutions

No salary listed

Germany

Hybrid

Hybrid role; on-site in Göttingen required, with some remote days.

Category
Finance & Banking (1)
Requirements
  • You have a bachelor’s degree in Business Administration, Finance, Human Resources, Information Systems, Engineering, Statistics or a related field
  • Relevant professional experience in sales operations, incentive compensation, or territory management, preferably in the life sciences or pharmaceutical industry
  • Proficiency in SAP Business Warehouse, SAP HANA, and analytical tools such as Tableau and Snowflake
  • Strong analytical and problem-solving abilities with excellent attention to detail
  • Proven experience working with large datasets and sales performance metrics
  • Thorough SQL and Python skills; Good knowledge of Salesforce data objects along with in-depth understanding of Lead to Cash process
  • Effective communicator with the ability to work cross-functionally and influence stakeholders at various levels
  • Ability to professionally manage and resolve disputes by effectively triaging issues, facilitating resolution, and ensuring timely outcomes
  • Experience with financial reporting and comfort discussing budgets and bonus impacts with Finance teams
  • Ability to manage multiple projects in a deadline-driven environment
  • Identification with our core values: Sustainability, Openness, Enjoyment
Responsibilities
  • Design and optimize data-driven sales incentive plans for global commercial teams to maximize revenue growth and sales-force motivation by benchmarking industry practices, modeling historical results, and running scenario analyses
  • Develop and maintain equitable territory structures and realignments for field representatives to ensure balanced market coverage and quota potential by integrating CRM data, market analytics, and feedback from sales leadership
  • Monitor, validate, and report sales performance KPIs and bonus calculations to guarantee accurate, timely payouts and reinforce plan credibility by automating data pipelines in Snowflake/Tableau and performing variance analyses
  • Investigate and resolve compensation or performance disputes raised by employees or managers to uphold trust and policy compliance by performing root-cause analysis and coordinating corrective actions with HR, Controlling, Customer Support Operations and other stakeholders
  • Partner with Data Governance colleagues to enforce data quality, consistency, and compliance across Sales systems by implementing validation controls and periodic audits
  • Liaise with Commercial Reporting and Advanced Analytics teams to translate complex data into actionable insights for sales leadership, enabling proactive course corrections and strategic decision-making
  • Educate and empower the sales organization through structured training sessions, up-to-date documentation, and open office-hour forums to drive incentive-plan understanding, boost engagement, and swiftly address general concerns or questions
  • Drive continuous improvement of TMIC processes, tools, and automation capabilities to enhance scalability, user experience, and audit readiness by leading cross-functional projects and adopting best-in-class technologies
Desired Qualifications
  • Experience with labor law considerations or Workers’ Council negotiations is a plus
  • Location: Göttingen hybrid role with on-site requirements could be a consideration for some candidates

Sartorius is a global partner in life sciences research and biopharmaceutical manufacturing. It provides laboratories with innovative instruments and consumables for research and quality control, and it offers Bioprocess Solutions focused on single-use systems that help manufacture biotech medicines, vaccines, and cell- and gene- therapies safely, quickly, and cost-effectively. Its products support the full path from drug discovery to commercial manufacturing, with a large worldwide footprint of more than 60 sites and a mission to help more people access better medicines. Sartorius differentiates itself through its broad portfolio spanning lab and bioprocess needs, a strong emphasis on single-use technologies, continuous portfolio expansion via acquisitions, and deep expertise serving pharmaceutical, biotech, and academic customers. Its goal is to simplify progress from research and development to scalable manufacturing so that life-saving medicines can reach patients worldwide.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Goldman Sachs upgrades Sartorius Stedim Biotech to Buy rating.
  • Sartorius achieves 3.5 billion euros sales revenue in 2025.
  • Management forecasts 5-9% sales growth for 2026 with MATTEK contributions.

What critics are saying

  • Thermo Fisher undercuts Sartorius bioreactors, capturing 15-20% market share.
  • Danaher's Cytiva launches Sartocon competitor with 30% higher throughput.
  • Chinese clones replicate Arium Mini at 40% lower cost, eroding Asia sales.

What makes Sartorius unique

  • Sartorius launches Arium Mini Extend for versatile Type 1 water dispensing.
  • Sartorius opens $100M Bioanalytics CoE in Ann Arbor, Michigan.
  • Sartorius partners with Sanofi on downstream process intensification.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Sartorius who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

Sartorius AG
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

INACTIVE